EISAI CO
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males
- First Posted Date
- 2014-08-26
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02225288
A Study of E6011 in Japanese Subjects With Rheumatoid Arthritis
- First Posted Date
- 2014-07-22
- Last Posted Date
- 2020-08-13
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 53
- Registration Number
- NCT02196558
A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: APD356 10 mgDrug: APD356 20 mgDrug: APD356 XR-20 mgDrug: APD356 10 mg matching PlaceboDrug: APD356 20 mg matching PlaceboDrug: APD356 XR-20 mg matching PlaceboDrug: APD356 XR-20 mg (orange tablet)Drug: APD356 XR-20mg (orange tablet, fed state)
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2016-02-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT02192515
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A
Completed
- Conditions
- Cervical Dystonia
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 150
- Registration Number
- NCT02175719
Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 707
- Registration Number
- NCT02175173
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia
Completed
- Conditions
- Cervical Dystonia
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 1647
- Registration Number
- NCT02175693
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 8662
- Registration Number
- NCT02162264
Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease
- First Posted Date
- 2014-06-12
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 3482
- Registration Number
- NCT02162251
A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2014-10-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT02146261
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
- First Posted Date
- 2014-05-09
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 517
- Registration Number
- NCT02135107